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Reactive oxygen species (ROS) have been   
implicated in inflammatory diseases including 
rheumatoid arthritis (Filippin et al., 2008), 
multiple sclerosis (Gilgun-Sherki et al., 2004), 
thyroiditis (Burek and Rose, 2008), and type 1 
diabetes (Chen et al., 2008). It has long been 
known  that  ROS  perform  essential  roles  in   
immune  responses  to  pathogens,  including 
bacterial killing through the production of   
superoxide by reduced nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidases during 
the respiratory burst in activated macrophages   
and neutrophils (Lambeth, 2004; Kanayama and 
Miyamoto, 2007). NADPH oxidase (NOX)– 
derived ROS are critical in host defense, as 
patients  with  chronic  granulomatous  disease 
(CGD) or mice engineered to lack components 
of  the  NOXs  have  increased  susceptibility  to   
infection (Morgenstern et al., 1997; Shiloh   
et al., 1999).
Other work has elucidated a role for ROS in 
modulating immune responses through effects 
on signal transduction cascades, although the 
biochemical mechanisms by which ROS modify 
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Reactive oxygen species (ROS) have an established role in inflammation and host defense, as 
they kill intracellular bacteria and have been shown to activate the NLRP3 inflammasome. 
Here, we find that ROS generated by mitochondrial respiration are important for normal 
lipopolysaccharide (LPS)-driven production of several proinflammatory cytokines and for 
the enhanced responsiveness to LPS seen in cells from patients with tumor necrosis factor 
receptor-associated periodic syndrome (TRAPS), an autoinflammatory disorder caused by 
missense mutations in the type 1 TNF receptor (TNFR1). We find elevated baseline ROS in 
both mouse embryonic fibroblasts and human immune cells harboring TRAPS-associated 
TNFR1 mutations. A variety of antioxidants dampen LPS-induced MAPK phosphorylation 
and inflammatory cytokine production. However, gp91phox and p22phox reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase subunits are dispensable for inflammatory 
cytokine production, indicating that NADPH oxidases are not the source of proinflammatory 
ROS. TNFR1 mutant cells exhibit altered mitochondrial function with enhanced oxidative 
capacity and mitochondrial ROS generation, and pharmacological blockade of mitochon-
drial ROS efficiently reduces inflammatory cytokine production after LPS stimulation in 
cells from TRAPS patients and healthy controls. These findings suggest that mitochondrial 
ROS may be a novel therapeutic target for TRAPS and other inflammatory diseases.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Creative 
Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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inflammatory symptoms and rare development of amyloido-
sis (Ravet et al., 2006). TNFR1 with these polymorphisms 
behave like WT receptors in terms of receptor trafficking and 
TNF binding (Lobito et al., 2006).
Other autoinflammatory diseases, such as those associated 
with mutations in NLRP3/cryopyrin or IL-1 receptor an-
tagonist, are specifically associated with IL-1 overproduc-
tion or excessive IL-1 signaling, and IL-1 blockade in these 
fever syndromes results in normalization of inflammatory pa-
rameters and robust clinical responses (Hoffman et al., 2004; 
Goldbach-Mansky et al., 2006). In TRAPS, however, hetero-
zygous TNFR1 mutant cells produce higher levels of a wide 
variety of inflammatory cytokines, including IL-1, TNF, 
and IL-6, in response to LPS stimulation as compared with 
WT cells, whereas TNFR1 homozygosity resembles TNFR1 
deficiency (Simon et al., 2010). Pharmacological blockade of 
IL-1 or TNF has only partial effects on TRAPS symptoms, 
with some patients progressing to amyloidosis even on these 
therapies (Hull et al., 2002).
We have shown that one way in which mutant TNFR1 
predisposes to enhanced inflammation in TRAPS is through 
increased activation of MAPKs, independent of TNF. Cells 
harboring TRAPS-associated TNFR1 mutations display spon-
taneous MAPK activation, as well as enhanced and prolonged 
MAPK activation after LPS stimulation (Simon et al., 2010). 
ROS can potentiate MAPK activation by inactivation of 
MAPK phosphatases through oxidation of their catalytic 
cysteine residues (Meng et al., 2002; Reth, 2002; Kamata   
et al., 2005). This leads to a sustained MAPK response that 
temporally resembles the MAPK response seen in TRAPS. 
For this reason, we have investigated the role that ROS play 
in abnormal signaling and inflammatory cytokine production 
in cells harboring TNFR1 mutations. ROS have been shown 
to contribute to normal inflammatory responses and to the 
pathophysiology of other autoinflammatory diseases. Recent 
work has demonstrated elevated baseline levels of ROS in the 
autoinflammatory  cryopyrin-associated  periodic  syndromes 
(CAPS; Tassi et al., 2010). It was shown that IL-1 production 
could be blocked using the antioxidant drug diphenylene   
iodonium (DPI) in both CAPS patients and healthy donors. 
However, recent work using NOX2-deficient CGD patient 
cells found no defect in IL-1 secretion (van de Veerdonk   
et al., 2010), contradicting the notion that DPI inhibits IL-1 
production through blockade of NOX-generated ROS. DPI 
has been shown, instead, to have an effect on transcription of 
inflammatory cytokine mRNA (van de Veerdonk et al., 
2010). Thus, the mechanism of action of DPI may extend 
beyond NOXs.
To investigate the role of ROS in inflammatory signaling 
and the source of ROS generation, we studied ROS levels in 
TRAPS patient cells and mouse embryonic fibroblasts (MEFs) 
derived from a mouse model in which heterozygous TNFR1 
mutations associated with TRAPS have been engineered into 
the mouse genome. We used antioxidants, genetic models, 
and metabolic measurements to exclude NOXs and identify 
the mitochondrial electron transport chain as the predominant 
these pathways are not always clear (Nathan, 2003). ROS have 
been implicated in the activation of signaling pathways such 
as  mitogen-activated  protein  kinases  (MAPK),  NF-B, 
and guanylate cyclase (Schmidt, 1992; Takada et al., 2003; 
Kamata et al., 2005), and have been shown to modulate   
B cell receptor signaling (Capasso et al., 2010), mast cell acti-
vation (Tagen et al., 2009), and cell adhesion (Sellak et al., 
1994). TNF-induced mitochondrial ROS have been impli-
cated in cell death through inhibition of MAPK phospha-
tases (Kamata et al., 2005). ROS have many sources, including 
peroxisomes, ubiquinone, cytosolic enzymes including cyclo-
oxygenase, uncoupled nitric oxide synthases, and ERO1 in 
the endoplasmic reticulum (Landmesser et al., 2003; Sevier 
and Kaiser, 2008). It is believed, however, that in cells under-
going aerobic metabolism, the majority of ROS are pro-
duced as a byproduct of the mitochondrial electron transport 
chain (Chance et al., 1979; Balaban et al., 2005).
Recently, a role for ROS has emerged in the activation 
of the NLRP3 inflammasome, one pathway for generation of 
active caspase-1 and secretion of mature IL-1 (Zhou et al., 
2010a).  The  NOX  enzymes  have  been  implicated  as  the 
source of ROS in inflammasome activation, as antioxidants 
thought to block NOXs and knockdown of p22 phagocyte 
oxidase (phox), a common subunit of four NOXs, resulted in 
diminished NLRP3 activation upon stimulation (Cruz et al., 
2007; Pétrilli et al., 2007; Dostert et al., 2008). More recent 
work shows a role for mitochondrial damage in NLRP3   
inflammasome  activation  (Zhou  et  al.,  2010b).  However, 
whether ROS directly activate the inflammasome has been 
called into question by data showing a distinct role for ROS 
in up-regulation of mRNA for inflammatory cytokines such 
as IL-1 and TNF(van de Veerdonk et al., 2010).
Tumor necrosis factor (TNF) receptor-associated periodic 
syndrome (TRAPS) is an autosomal dominant autoinflam-
matory disease associated with enhanced innate immune re-
sponsiveness. TRAPS is characterized clinically by recurrent 
fevers, abdominal pain (peritonitis), migratory rash, myalgia, 
and arthralgia. As with other autoinflammatory diseases, 
TRAPS can be complicated by the development of systemic 
amyloidosis caused by chronic inflammation and production 
of serum amyloid A (Hull et al., 2002). TRAPS is caused by 
mutations in the extracellular domain of the gene encoding 
TNF receptor 1 (TNFR1, TNFRSF1A, CD120a, and p55-
TNFR), and >50 individual mutations have been identified 
to date (Touitou et al., 2004). TNFR1 is a prototypic member 
of the TNF superfamily, capable of inducing inflammation 
and cell death. TNFR1 molecules harboring TRAPS-associated 
mutations fail to interact with WT TNFR1 receptors or 
TNF and traffic abnormally in the cell, with retention and 
accumulation  in  the  endoplasmic  reticulum  (Todd  et  al., 
2004; Lobito et al., 2006; Simon et al., 2010). These muta-
tions are referred to as structural mutations and are not found 
in the general population. Rare polymorphisms in TNFR1, 
such as those encoding R92Q and P46L mutations, are present 
in up to 5% of the healthy population and can also be associated 
with a TRAPS-like phenotype; these patients have milder JEM VOL. 208, March 14, 2011 
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source  of  ROS  responsible  for  physiological  inflammatory   
cytokine production in normal cells, as well as the hyper-
production of cytokines in cells from TRAPS patients and 
TRAPS model mice.
RESULTS
ROS are increased in cells harboring TRAPS-associated 
TNFR1 mutations
We have previously observed that MAPK activation is in-
creased in cells harboring TRAPS-associated TNFR1 muta-
tions and that exaggerated inflammatory responses in TRAPS 
depend on p38 and JNK MAPK (Simon et al., 2010). Because 
ROS are known to inactivate MAPK phosphatases and   
perpetuate MAPK activation (Kamata et al., 2005), we hy-
pothesized that increased ROS may underlie the exaggerated 
MAPK signaling and inflammatory responses in TRAPS. We 
therefore investigated the baseline and induced levels of ROS 
in cells harboring TRAPS-associated TNFR1 mutations with 
the  redox-sensitive  probe  dihydrorhodamine  123  (DHR). 
DHR, which rapidly diffuses through the cell membrane and 
is oxidized into the fluorescent compound rhodamine by free 
radicals, measures the total oxidative capacity of a cell. In T50M 
and C33Y TNFR1 heterozygous MEFs, we found that baseline 
ROS levels were elevated. The increase was small, but con-
sistent and statistically significant. As expected, phorbol-12-
myristate-13-acetate (PMA), which induces cells to undergo 
the NOX–dependent respiratory burst, further increased the 
ROS levels in both normal and mutant cells, but not out of 
proportion to the baseline levels. In contrast, LPS stimulation 
did not induce further ROS production in either normal or 
mutant cells (Fig. 1 A).
To determine whether elevated ROS could be detected 
in TRAPS patient cells, we examined ROS levels using the 
DHR assay in monocytes and neutrophils isolated from 
TRAPS patients with either structural TNFR1 mutations or 
TNFR1 polymorphisms, healthy control donors, or patients 
with the autoinflammatory disease familial Mediterranean   
fever. We found significantly elevated ROS levels at baseline 
in monocytes from TRAPS patients with structural TNFR1 
mutations compared with monocytes from the other three 
groups (Fig. 1 B). After induction of the respiratory burst 
with PMA, the increase in ROS over baseline was not signif-
icantly different between monocytes from TRAPS patients 
and healthy controls. Similar to the MEFs, neither TRAPS 
patient nor control cells responded to LPS with an increase in 
ROS production (Fig. S1 A). We also examined neutrophils, 
which produce large amounts of ROS during the respiratory 
Figure 1.  Increased ROS in TNFR1 mutant cells and peripheral  
blood cells from TRAPS patients. (A) WT, C33Y TNFR1 heterozygous,  
and T50M TNFR1 heterozygous MEFs were left untreated (UT) or were 
treated with PMA or LPS for 1 h. Cells were incubated with DHR and ROS 
levels were determined by flow cytometry. Bar graph shows results of 
four independent experiments and histograms show one representative 
experiment. n.s., not significant. Error bars represent the mean ± SEM.  
(B) Monocytes and neutrophils from healthy donors (n = 27–31), TRAPS 
patients with structural mutations (TRAPS structural; n = 11–13), TRAPS 
patients with R92Q polymorphisms (TRAPS poly; n = 6), or patients with 
familial Mediterranean fever (FMF; n = 7) were treated for 1 h with or 
without PMA. Cells were incubated with DHR, and ROS levels were deter-
mined by flow cytometry. Data are from 10 experiments; each symbol repre-
sents a unique patient. (C) PBMCs and neutrophils from healthy donors  
(n = 25–33), TRAPS patients with structural mutation (TRAPS structural;  
n = 13–16) and TRAPS patients with R92Q or P46L polymorphisms (TRAPS 
poly; n = 4) were analyzed for superoxide production with a kinetic chemi-
luminescent assay in the presence or absence of PMA. Data are from  
11 experiments; each symbol represents a unique patient. RLU, relative 
luminescence units. Data were normalized to the mean WT or healthy  
donor result for each experiment. *, P ≤ 0.05; **, P < 0.01.
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To determine the role of ROS in inflammatory cytokine 
production, we measured effects of ROS inhibitors on the 
production of IL-6 by WT and heterozygous TNFR1 mutant 
MEFs, which overproduce IL-6 when exposed to LPS (Simon 
et al., 2010). In addition to NAC, we also used DPI, which 
acts as a competitive inhibitor of flavin-containing cofactors 
and is a particularly potent inhibitor of NOX enzymes (Holland 
and Sherratt, 1972). As previously described, C33Y and T50M 
TNFR1 heterozygous MEFs produce excess IL-6 in response 
to LPS compared with WT cells (Fig. 2 B). NAC and DPI 
significantly blocked excess IL-6 production by TNFR1 mutant 
cells and, interestingly, also effectively blocked IL-6 production 
in WT cells (Fig. 2 B), suggesting that there is a role for ROS 
in the normal inflammatory response to LPS. IFN-, which 
is expressed independently of MAPK signaling, was neither 
hyperproduced by TNFR1 mutant MEFs nor reduced by the 
addition of antioxidants. The role of ROS in IL-6 signaling 
is transcriptional, as induction of IL-6 mRNA by LPS in WT 
and TNFR1 mutant cells was also inhibited by NAC and 
DPI (Fig. 2 C). Neither of these antioxidants significantly   
affected cell viability (Fig. S2, A and B).
To determine the significance of these findings in human 
immune cells, we measured the effects of these antioxidants 
on PBMCs from TRAPS patients and healthy donors. We 
have previously shown that PBMCs from TRAPS patients 
produce excess TNF and IL-6 in response to LPS (Simon   
et al., 2010). NAC and DPI both decreased IL-6, TNF, and 
IL-10 production in the TRAPS patient cells back to the 
levels produced by cells from healthy donors, whereas DPI 
decreased CXCL8/IL-8 production (Fig. 2 D). In addition, 
both NAC and DPI significantly lowered cytokine production 
by PBMCs from healthy donors, supporting a role for ROS 
in physiological LPS-induced inflammation as well. IFN- 
and CCL5/RANTES, both activated by IRF3, were unaffected 
by antioxidant treatment. This suggests that the efficacy of 
the antioxidants correlates with dependency on MAPKs, as 
induction of IL-6, TNF, CXCL8/IL-8, and IL-10 are depen-
dent on MAPKs (Scherle et al., 1998; Chi et al., 2006). Col-
lectively, these results strongly implicate ROS in physiological 
production of cytokines after TLR4 stimulation in normal 
cells, and in the maintenance of MAPK activity and excess 
inflammatory cytokine production in cells harboring TRAPS-
associated TNFR1 mutations.
ROS generated by NOXs are not required for inflammatory 
cytokine production in TNFR1 mutant and normal cells
Based on the potency of DPI in the aforementioned experi-
ments, we sought to identify whether NOXs might be the 
source of ROS responsible for inflammatory cytokine pro-
duction in normal and TNFR1 mutant cells. NOX2 partici-
pates directly in the innate immune response against foreign 
pathogens and is a major generator of ROS in monocytes, 
leading us to study NOX2 as a potential candidate for gener-
ating the ROS that supports inflammatory cytokine produc-
tion. Mice with a null allele of the gene involved in X-linked 
CGD, gp91phox, which encodes the 91-kD subunit of the 
burst (Nathan, 2006). We could not detect elevated baseline 
or induced ROS in neutrophils from TRAPS patients using 
this assay. We found no correlation between elevated ROS in 
TRAPS patient cells and C-reactive protein, specific TNFR1 
mutation, flare status, or medications, suggesting that increased 
ROS production is an intrinsic feature of TRAPS rather than 
a result of symptoms or treatment at the time of sample collec-
tion (Fig. S1 B). We also measured ROS production with a 
luminol-based method that is very sensitive for superoxide 
production, and found higher baseline ROS levels in PBMCs 
from TRAPS patients with structural TNFR1 mutations, but 
similar induction of the respiratory burst with PMA (Fig. 1 C). 
In addition, the increased sensitivity of the luminol-based assay 
allowed detection of a slight elevation in neutrophil ROS 
levels in TRAPS cells that was not evident using the DHR 
assay. Although PBMCs from patients with TNFR1 polymor-
phisms appeared to generate less ROS using luminol detection, 
this is not likely to have functional consequences, as it has been 
previously shown that PBMCs from patients with TNFR1 
polymorphisms respond normally to LPS (Simon et al., 2010). 
Collectively, these data indicate a baseline elevation in ROS 
production in TRAPS that is most pronounced in monocytes.
ROS mediate increased MAPK signaling and inflammatory 
responses in TNFR1 mutant cells
To determine the role of ROS in inflammatory responses to 
LPS, we measured the effects of ROS inhibition on MAPK 
activation and cytokine production. We first measured the 
effect of ROS inhibition on MAPK phosphorylation in cells 
from normal mice and mice heterozygous for TNFR1 muta-
tions. The free radical scavenger N-acetylcysteine (NAC) 
neutralizes ROS as they are generated, providing a broad in-
dication of the role of ROS in biological processes. As previ-
ously described, TNFR1 mutant MEFs stimulated with LPS 
exhibited sustained phosphorylation of JNK, p38, and ERK 
for up to 120 min compared with WT cells, in which acti-
vation of these kinases peaked at 30 min, followed by a rapid 
decline (Simon et al., 2010). Because ROS prevent the de-
phosphorylation of MAPKs, we reasoned that ROS inhibi-
tors may reduce the abnormally sustained MAPK activation 
in the setting of TNFR1 mutations. Indeed, NAC effectively 
reduced the sustained JNK and p38 phosphorylation at the 
2-h time point in TNFR1 heterozygous mutant MEFs and, 
to a lesser extent, in WT MEFs (Fig. 2 A). Phosphorylation 
of ERK was not as affected by NAC in TNFR1 mutant cells, 
but  we  have  previously  shown  that  exaggerated  cytokine 
production by TRAPS cells is dependent on p38 and JNK 
kinases more than ERK family kinases (Simon et al., 2010). 
Although NAC has been shown to inhibit the activation of both 
NF-B and IRF3, we have not seen increased activation   
of NF-B or IRF3, or increased production of the IRF3- 
dependent cytokine CCL5/RANTES in TRAPS (Simon   
et al., 2010). It is likely that NAC affects all of these signal-
ing  pathways,  but  specifically  abrogates  TRAPS  hyper-
responsiveness through effects on pathologically elevated p38   
and JNK phosphorylation.JEM VOL. 208, March 14, 2011 
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have increased neutrophil infiltration in a sterile peritonitis 
model (Pollock et al., 1995).
To determine whether removal of NOX2-generated ROS 
would reverse or weaken the hyperinflammatory phenotype in 
TNFR1 mutant macrophages, we crossed gp91phox-null mice to 
TNFR1 C33Y heterozygous mice on an isogenic C57BL/6 
background. Peritoneal macrophages from all of the mice 
oxidase flavocytochrome b558, lack phagocyte superoxide 
production by NOX2 and have increased susceptibility to 
infection with Staphylococcus aureus and Aspergillus fumigatus 
(Pollock et al., 1995). Despite this immunodeficiency, mac-
rophages from gp91phox-null mice, as well as CGD patients, 
produce increased inflammatory cytokines in response to 
sterile innate stimuli such as LPS (Bylund et al., 2007) and 
Figure 2.  Role of ROS in LPS-induced MAPK activation and cytokine production in normal and TNFR1 mutant cells. (A) WT and C33Y  
TNFR1 heterozygous MEFs were treated with or without NAC for 30 min, and further treated with LPS for the indicated time, after which JNK, p38, and 
ERK phosphorylation were measured by Western blot. Numbers shown are the density of each phosphoprotein relative to nonphosphorylated protein, 
normalized to the WT untreated sample. Actin is included as a loading control. Data are representative of three independent experiments. (B) WT, C33Y 
TNFR1 heterozygous, and T50M TNFR1 heterozygous MEFs were treated with LPS in the presence of the indicated antioxidants. IL-6 and IFN- were  
measured in supernatants. Levels produced by WT MEFs after LPS stimulation ranged from 11.5–104.5 pg/ml (IL-6) and 13.5–23.0 pg/ml (IFN-; n = 4 
independent experiments). Data were normalized to the average WT result for each experiment. (C) IL-6 mRNA was measured by qRT-PCR in MEFs of  
the indicated genotype treated for 6 h with LPS and the indicated antioxidants, as in B. Data are shown as fold induction to LPS (as compared with  
untreated), and are representative of three experiments. (D) PBMCs from healthy donors (n = 5–6) and TRAPS patients with structural mutation (n = 4–7) 
were incubated with LPS and the indicated antioxidants, as in B. IL-6, TNF, CXCL8/IL-8, IL-10, IFN-, and CCL5/RANTES were measured in supernatants. 
Levels produced by cells from healthy donors after LPS stimulation ranged from 2.36–9.98 ng/ml (IL-6), 0.21–2.04 ng/ml (TNF), 5.7–77.7 ng/ml  
(CXCL8/IL-8), 0.054–0.334 ng/ml (IL-10), 0.010–0.058 ng/ml (IFN-), and 0.138–0.979 ng/ml (CCL5/RANTES; n = 3–5 independent experiments). Error  
bars represent the mean ± SEM. Data were normalized to the average healthy donor result for each experiment. *, P ≤ 0.05; **, P < 0.01.524 Mitochondrial ROS in autoinflammation | Bulua et al.
lacking the gp91phox subunit produced no detectable superoxide 
after stimulation with PMA (Fig. S3 A). Like the parental strains, 
heterozygous TNFR1 mutant gp91phox-null mice had no overt 
phenotype. As previously described (Simon et al., 2010), macro-
phages from the TNFR1 mutant mice produced more IL-6, 
TNF, and IL-1 than WT macrophages in response to LPS. 
Macrophages from gp91phox-null mice produced similar, if not 
higher, levels of these cytokines as compared with TNFR1 mu-
tant cells, and the hyperresponsiveness seen in TRAPS was not 
lessened in the absence of NOX2-generated ROS (Fig. 3 A). 
These results clearly show that NOX2-generated ROS are not 
required for inflammatory cytokine production by macrophages, 
in either TRAPS or normal cells.
To determine whether a NOX family member besides 
NOX2 may be responsible for ROS generation and the sub-
sequent inflammatory sequelae in the CGD model and in 
TRAPS, we studied NMF333 mice, which harbor a naturally 
occurring mutation in the p22phox subunit common to NOX1, 
2, 3, and 4 (Nakano et al., 2008). After PMA stimulation, 
macrophages from these mice produced no detectable respira-
tory burst (Fig. S3 B). However, we discovered that after stim-
ulation with LPS, macrophages from these mice, similar to 
NOX2-deficient mice, produced elevated levels of IL-6, TNF, 
and IL-1 (Fig. 3 B) in comparison to isogenic controls. These 
data show that ROS generated by NOXs containing p22phox 
are not required for inflammatory cytokine production by mac-
rophages. Interestingly, addition of DPI still strongly blocked 
the production of inflammatory cytokines in p22phox mutant 
macrophages (Fig. 3 B). Thus, the antiinflammatory effect of 
DPI is independent of its effects on NOXs containing p22phox.
ROS have been implicated in the activation of the NLRP3 
inflammasome, which results in IL-1 processing and secretion 
through activation of caspase-1 (Cruz et al., 2007; Zhou et al., 
2010a). Thus, we considered that ROS may play a role in IL-6 
and TNF production through positive feedback from IL-1. 
To determine if this was the case, we tested the response of 
Nlrp3/, Casp1/, and Il1r1/ macrophages to LPS. As ex-
pected, macrophages from Nlrp3/ and Casp1/ mice   
generated no detectable IL-1 in response to LPS, whereas 
macrophages from Il1r1/ mice had no defect in IL-1 pro-
duction. However, LPS-stimulated cells from each of these mice 
produced normal levels of IL-6 and TNF (Fig. 3 C). Therefore, 
production of these cytokines in response to LPS is not the 
result of NLRP3-dependent IL-1 production, nor is it down-
stream of other NLRP3- or caspase-1–dependent cytokines. 
Collectively, these data suggest that normal production of in-
flammatory cytokines other than IL-1, as well as the increased 
cytokine responsiveness in TRAPS, is dependent on ROS, 
but not through effects of ROS on the inflammasome.
Inflammatory cytokine production is linked to mitochondrial 
ROS production in TRAPS and normal cells
Given that DPI works through the inhibition of flavin- 
containing enzymes, there are several other ROS generators 
that may be responsible for producing proinflammatory ROS. 
In fact, DPI was first identified as an inhibitor of mitochondria 
Figure 3.  NOX-derived ROS and the inflammasome are not  
required for LPS-induced cytokine production. (A) Peritoneal macro-
phages from mice of the indicated genotypes were stimulated with LPS 
for 6 h, and ATP for the final 15 min, before measuring IL-6, TNF, and  
IL-1 in the supernatants. Levels produced by WT mice after LPS stimula-
tion ranged from 1.52–1.61 ng/ml (IL-6), 0.23–0.97 ng/ml (TNF), and  
0.21–0.46 ng/ml (IL-1; n = 2 independent experiments, 1 mouse in each 
group). (B) Peritoneal macrophages from mice of the indicated genotypes 
were incubated with LPS in the presence or absence of DPI for 6 h, and 
ATP for the final 15 min, before measuring IL-6, TNF, and IL-1 in the 
supernatants. Levels produced by WT mice after LPS stimulation ranged 
from 1.52–4.49 ng/ml (IL-6), 0.14–0.19 ng/ml (TNF), and 3.10–4.07 ng/ml 
(IL-1; n = 3 independent experiments, one mouse in each group).  
(C) Peritoneal macrophages from mice of the indicated genotypes were 
stimulated with LPS for 6 h, and ATP for the final 15 min, before measuring  
IL-6, TNF, and IL-1 in the supernatants. Levels produced by WT mice 
after LPS stimulation ranged from 1.68–2.70 ng/ml (IL-6), 0.39–0.58 ng/ml 
(TNF), and 0.18–0.80 ng/ml (IL-1; n = 3 independent experiments, one 
mouse in each group). nd, not detectable. Error bars represent the  
mean ± SEM. Data were normalized to the average WT LPS result for  
each experiment. *, P ≤ 0.05; **, P < 0.01.
(Holland and Sherratt, 1972), as it blocks the flavin compo-
nents of the electron transport chain. However, DPI was later 
shown to be less potent as an inhibitor of mitochondrial oxi-
dative phosphorylation than NOX enzymes (Hancock and 
Jones, 1987) and nitric oxide synthases (Stuehr et al., 1991). JEM VOL. 208, March 14, 2011 
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For this reason, the effects of DPI are most commonly attrib-
uted to inhibition of NOX enzymes, even when used at high 
doses (≥10 µM; Dostert et al., 2008; Martinon et al., 2010; 
van de Veerdonk et al., 2010). We took advantage of the differ-
ential potency of DPI on NOXs and mitochondria to deter-
mine the relevant target for its antiinflammatory effects. In intact 
MEFs, DPI reduced mitochondrial oxygen consumption as 
effectively as rotenone, a standard blocker of complex I, at the 
same concentration at which it affects cytokine production   
(5 µM). Lowering the concentration of DPI reduced its inhi-
bition of oxygen consumption in a dose-dependent manner, 
with little inhibition below 0.5 µM (Fig. 4 A).
DPI has been shown to block mitochondrial ROS, which 
are produced as a consequence of electron leak during the 
electron transport chain (Li and Trush, 1998); it inhibits   
flavin adenine dinucleotide (FAD), which is present in both 
complex I (NADH-quinone oxidoreductase) and complex II 
(succinyl dehydrogenase). Using the MitoSOX Red dye, a 
probe of mitochondrial superoxide production in live cells, 
we found that DPI inhibits mitochondrial ROS in the same 
dose range at which it inhibits oxygen consumption (Fig. 4 B). 
To correlate these findings with LPS-induced inflammatory 
cytokine production, we added these same concentrations of 
DPI to LPS-stimulated MEFs. Concentrations of DPI that 
inhibited mitochondrial ROS generation also inhibited in-
flammatory cytokine production in the same dose-dependent 
manner (Fig. 4 C). At doses down to 0.05 µM, however,   
DPI was equally effective at inhibiting PMA-induced ROS, 
which can be attributed to NOX enzymes (Fig. 4 D). These 
data strongly point to mitochondrial respiration, not NOXs, 
as the source of ROS involved in LPS-induced inflammatory 
cytokine production.
Rather than ROS, it is possible that the ATP generated 
through mitochondrial respiration might be the driving force 
behind inflammatory responses to LPS. To determine whether 
this is the case, we used rotenone, an effective electron transport   
inhibitor (Fig. 4 A). Although rotenone has been shown to   
both increase and decrease mitochondrial ROS production in a 
variety of cell types (Li et al., 2003; Thompson et al., 2007), 
Figure 4.  Inhibition of mitochondrial oxygen consumption by DPI. 
(A) The effect of antioxidants on oxygen consumption rate was measured 
in WT MEFs with a Seahorse Bioscience XF Analyzer. The arrow indicates 
time of addition of the antioxidants. A representative plot (n = 3) is 
shown. (B) WT MEFs were incubated with the indicated antioxidants for  
1 h or were left untreated and then stained with MitoSOX Red, and ROS 
levels were determined by flow cytometry. Data were normalized to the 
untreated result (n = 3 independent experiments). (C) WT MEFs were 
treated with LPS and the indicated concentrations of DPI, after which IL-6 
was measured in supernatants. Levels of IL-6 were normalized to the LPS 
alone result, which ranged from 0.284–0.321 ng/ml (n = 3 independent  
experiments). (D) WT MEFs were treated with PMA and the indicated con-
centrations of DPI for 1 h. Cells were incubated with DHR, and ROS levels 
were determined by flow cytometry. Data were normalized to the increase 
in fluorescence (as compared with untreated) of the PMA alone sample 
for each experiment (n = 3 independent experiments). (E) WT, C33Y TNFR1 
heterozygous, and T50M TNFR1 heterozygous MEFs were treated with LPS 
in the presence or absence of rotenone, after which IL-6 was measured  
in supernatants. IL-6 levels were normalized to the WT LPS alone result, 
which ranged from 11.5–104.5 pg/ml (n = 4 independent experiments).  
(F) PBMCs from healthy donors (n = 6) and TRAPS patients with structural 
mutations (n = 6) were incubated with LPS in the presence or absence of 
rotenone, after which IL-6 and TNF were measured in the supernatants. 
IL-6 and TNF levels were normalized to the healthy donor LPS alone result, 
which ranged from 1.31–2.28 ng/ml (IL-6) and 0.274–0.661 ng/ml (TNF;  
n = 6 independent experiments). Error bars represent the mean ± SEM.
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consumption, and both C33Y and T50M heterozygous TNFR1 
mutant MEFs have significantly increased maximum oxidative 
capacity measured after addition of the electron transport un-
coupler dinitrophenol (Fig. 5, C and D). In support of altered 
mitochondrial respiration, the mitochondrial membrane po-
tential measured with the potentiometric dye TMRM was 
increased in TNFR1 mutant MEFs (Fig. 5 E). The higher 
ATP levels in cells harboring TNFR1 mutations is not caused 
by a glycolytic source, as the extracellular acidification rate 
in the TNFR1 mutant MEFs was similar to that of the WT 
MEFs (Fig. 5 F). Although the increased oxygen consumption 
observed in TNFR1 mutant cells could be caused by increased 
mitochondrial content, mitochondrial copy number in TNFR1 
mutant MEFs was not significantly different from WT controls 
(Fig. 5 G). PBMCs from TRAPS patients  with  structural 
TNFR1 mutations asymptomatic at the time of sample col-
lection also showed alterations in mitochondrial function; 
they displayed elevated basal oxygen consumption and in-
creased oxygen consumption after addition of dinitrophenol 
as compared with healthy controls (Fig. 5 H, I). This suggests 
that PBMCs containing TNFR1 mutations have a greater 
capacity for mitochondrial respiration.
we found that it does not affect mitochondrial ROS production 
in MEFs at time points that are relevant to signaling (Fig. 4 B). 
Overall, rotenone was not effective at blocking inflammatory 
cytokine production in either MEFs (Fig. 4 E) or human PBMCs 
(Fig. 4 F), suggesting that an intact electron transport chain is not 
required for inflammatory cytokine production. These data 
point to mitochondrial ROS rather than ATP as the proinflam-
matory signal generated by mitochondria.
Mitochondrial function and mitochondrial ROS production 
are altered in TRAPS
We reasoned that cells harboring heterozygous TNFR1 mu-
tations associated with TRAPS might exhibit increased basal 
mitochondrial electron transport and oxidative phosphoryla-
tion, which could lead to increased inflammatory responses. 
Measurement of total ATP levels with a luminol-based reagent 
showed that heterozygous TNFR1 mutant MEFs (Fig. 5 A) 
and PBMCs from TRAPS patients with structural TNFR1 
mutations (Fig. 5 B) both exhibit a small but significant   
increase in ATP levels over controls. Measurement of oxy-
gen consumption showed that heterozygous C33Y TNFR1 
mutant MEFs have a significantly higher level of basal oxygen   
Figure 5.  Increased ATP levels and  
oxidative capacity in cells with TRAPS-
associated TNFR1 mutations. (A) ATP level 
was measured in WT and TNFR1 mutant  
MEFs. Cell numbers were determined with a 
CyQuant assay, and data were normalized  
to the WT result (n = 5 independent experi-
ments). RLU, relative luminescence units.  
(B) ATP level was measured in PBMCs from 
healthy donors (n = 8) and TRAPS patients 
with structural mutations (n = 6). Cell num-
bers were determined with a CyQuant assay, 
and data were normalized to the healthy  
donor result (n = 4 independent experiments). 
RLU, relative luminescence units. (C) Oxygen 
consumption was measured in WT, C33Y TNFR1 
heterozygous, and T50M TNFR1 heterozygous 
MEFs using the Seahorse Bioscience XF Ana-
lyzer. Dinitrophenol was added as indicated  
by the arrow. A representative plot (n = 3) is 
shown. (D) Basal and maximum oxygen  
consumption were determined in MEFs of  
the indicated genotypes using the Seahorse 
Bioscience XF Analyzer (n = 3 independent 
experiments). (E) TMRM staining of WT, C33Y 
TNFR1 heterozygous, and T50M TNFR1 het-
erozygous MEFs was determined by flow  
cytometry. A representative histogram (n = 3) 
is shown. (F) Extracellular acidification was measured in WT, C33Y TNFR1 heterozygous, and T50M TNFR1 heterozygous MEFs using the Seahorse Bioscience  
XF Analyzer (n = 3 independent experiments). (G) Mitochondrial copy number was measured by qRT-PCR in MEFs of the indicated genotypes. Cytb mito-
chondrial DNA was compared with 18S genomic DNA (n = 2 independent experiments). (H) Oxygen consumption was measured in PBMCs from healthy 
donors (n = 10) and patients with TRAPS structural mutations (n = 6) using the Seahorse Bioscience XF Analyzer. Dinitrophenol was added as indicated  
by the arrow. A representative plot with two healthy donors and two TRAPS patients with structural mutations is shown (n = 5 independent experiments). 
(I) Basal and maximum oxygen consumption were determined from healthy donors (n = 10) and TRAPS patients with structural mutations (TRAPS structural;  
n = 6) using the Seahorse Bioscience XF Analyzer. Error bars represent the mean ± SEM. Data were normalized to the average healthy donor result (n = 5  
independent experiments). *, P ≤ 0.05; **, P < 0.01.JEM VOL. 208, March 14, 2011 
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seen in WT MEFs as well as TNFR1 mutant cells (Fig. 7 B). 
Importantly, MitoQ suppressed the production of IL-6, TNF, 
CXCL8/IL-8, and IL-10 in PBMCs from TRAPS patients 
back to the levels produced by control cells from healthy   
donors, and also suppressed the production of these cytokines 
by cells from healthy donors in response to LPS (Fig. 7 C). 
IFN- and CCL5/RANTES production in response to LPS 
was unaffected by the addition of MitoQ, suggesting that   
the efficacy of MitoQ is through its action on MAPKs and 
To more directly measure mitochondrial ROS produc-
tion in cells harboring TNFR1 mutations, we used MitoSOX 
Red. Unlike DHR, MitoSOX Red staining in MEFs did not 
increase in response to the NOX-mediated respiratory burst, 
indicating  that  the  dye  is  more  specific  to  mitochondrial 
ROS. In addition, MitoSOX Red staining did not increase 
in response to LPS stimulation, suggesting that there is not an 
acute increase in mitochondrial ROS generation during an 
inflammatory response (Fig. S4 A). Both C33Y and T50M 
TNFR1  heterozygous  mutant  MEFs  showed  significantly 
higher spontaneous mitochondrial ROS generation than WT 
MEFs (Fig. 6 A). PBMCs from TRAPS patients with structural 
TNFR1 mutations, but not TNFR1 polymorphisms, also pro-
duced significantly higher mitochondrial ROS than PBMCs 
from healthy donors (Fig. 6 B). Excess mitochondrial super-
oxide stimulates increased transcription of MnSOD, a mito-
chondrial-specific superoxide dismutase (Miao and St Clair, 
2009; Pani et al., 2009). To determine if the increased mito-
chondrial superoxide production measured in TRAPS is   
sufficient to induce this biological response, we measured 
MnSOD transcripts in TNFR1 mutant MEFs and PBMCs 
from patients with TRAPS structural mutations by quantita-
tive RT-PCR (qRT-PCR). We found more than a twofold 
higher level of MnSOD mRNA at baseline in both of these 
cell types (Fig. 6, C and D). mRNA of the endogenous anti-
oxidant thioredoxin was slightly higher in PBMCs from 
TRAPS patients with structural mutations as compared with 
healthy donors, but not as highly elevated as MnSOD (Fig. 6 D). 
These data show that TNFR1 mutations in TRAPS stimulate 
increased mitochondrial oxidative capacity and ROS pro-
duction, leading to an antioxidant response associated with 
chronic oxidative stress.
Inhibition of mitochondrial ROS reduces IL-6 production
If mitochondrial ROS play an important role in inflammatory 
cytokine production, ROS scavengers specific to mitochon-
drial ROS should block LPS-induced inflammatory cytokine 
production with particular efficacy. Mitoquinone (MitoQ), a 
coenzyme Q10 analogue that acts as a ROS scavenger, con-
tains a lipophilic triphenylphosphonium cation that causes 
the antioxidant to accumulate several hundredfold within 
mitochondria because of the high mitochondrial membrane 
potential (Murphy and Smith, 2007; Villalba et al., 2010). 
MitoQ has been shown to effectively decrease mitochondrial 
ROS levels, both at baseline and after the addition of respiratory 
chain inhibitors that increase mitochondrial ROS (Chernyak 
et al., 2006). Decyl-TPP bromide (dTPP), which contains 
the same lipophilic cation but has no antioxidant activity, was 
used as a control. Neither MitoQ nor dTPP affected oxygen 
consumption (Fig. S4 B) or cell viability (Fig. S2, A and B). 
MitoQ reduced LPS-induced IL-6 production in C33Y and 
T50M TNFR1 heterozygous MEFs nearly back to the levels 
secreted by WT cells (Fig. 7 A). However, IFN- levels were 
not reduced by the addition of MitoQ (Fig. 7 A). Like DPI, 
the inhibition of IL-6 production by MitoQ was at the tran-
scriptional level, and inhibition of IL-6 transcription could be 
Figure 6.  Mitochondrial superoxide production is increased in 
TRAPS. (A) WT, C33Y TNFR1 heterozygous, and T50M TNFR1 heterozygous 
MEFs were incubated with MitoSOX Red for 1 h and ROS levels were de-
termined by flow cytometry. Histogram shows representative staining and 
bar graph shows results of three independent experiments. Data were 
normalized to the average WT result for each experiment. (B) Monocytes 
from healthy donors (n = 15), TRAPS patients with structural mutations 
(TRAPS structural; n = 9), and TRAPS patients with TNFR1 polymorphisms 
(TRAPS poly; n = 5) were incubated with MitoSOX Red for 1 h, and ROS 
levels were determined by flow cytometry. Histogram shows representa-
tive staining and bar graph shows results of six independent experiments; 
each symbol represents a unique patient. Data were normalized to the 
average healthy donor result for each experiment. (C) SOD2 mRNA was 
measured by qRT-PCR in MEFs of the indicated genotype (n = 3 independent 
experiments). Data represent gene expression relative to 2-microglobulin. 
(D) SOD2 and thioredoxin mRNA were measured by qRT-PCR in PBMCs 
from healthy donors (n = 6–7) and TRAPS patients with structural muta-
tions (n = 14). Data represent gene expression relative to 2-microglobulin. 
Error bars represent the mean ± SEM. *, P ≤ 0.05; **, P < 0.01.528 Mitochondrial ROS in autoinflammation | Bulua et al.
inflammatory response. If mitochondrial respiration or ROS 
production is inhibited, inflammatory cytokine production 
in response to LPS is blunted. In TRAPS, increased mito-
chondrial ROS production inactivates MAPK phosphatases 
and leads to sustained MAPK activity that enhances innate 
immune responses (Fig. 7 D). Multiple lines of evidence   
implicate mitochondrial respiration as a source of ROS that 
supports normal inflammatory responses to LPS and drives 
hyperinflammation in TRAPS: (a) the concentrations of DPI 
that block mitochondrial respiration and ROS correlate with 
its antiinflammatory effects; (b) DPI and MitoQ are the most 
effective at suppressing inflammatory cytokine production in 
independent of IRF3. These data identify mitochondrial 
ROS as an important component of the inflammatory response, 
both in normal cells and in the hyperresponsiveness of cells 
harboring TNFR1 mutations in TRAPS.
DISCUSSION
Through the measurement of cellular respiration in intact cells 
and the use of targeted antioxidants, we demonstrate here 
that alterations in baseline mitochondrial ROS production 
can affect LPS-induced cytokine production. We propose   
a model in which mitochondrial ROS support a balance be-
tween MAP kinases and phosphatases that results in the normal 
Figure 7.  Inhibition of mitochondrial ROS can reduce normal cytokine production and reverse hyperinflammatory responses in TRAPS.  
(A) WT, C33Y TNFR1 heterozygous, and T50M TNFR1 heterozygous MEFs were treated with LPS in the presence of the mitochondrial ROS scavenger MitoQ 
and its control, dTPP. IL-6 and IFN- were measured in supernatants. Levels produced by WT MEFs after LPS stimulation ranged from 11.5–104.5 pg/ml  
(IL-6) and 13.5–23.0 pg/ml (IFN-; n = 3 independent experiments). (B) IL-6 mRNA was measured by qRT-PCR in MEFs of the indicated genotype treated 
for 6 h with LPS and the indicated reagents as in A. Data are shown as fold induction to LPS (as compared with untreated), and are representative of  
three independent experiments. (C) PBMCs from healthy donors (n = 5–8) and TRAPS patients with structural mutations (TRAPS structural; n = 4) were 
incubated with LPS and the indicated reagents as in A. IL-6, TNF, CXCL8/IL-8, IL-10, IFN-, and CCL5/RANTES were measured in supernatants. Levels  
produced by PBMCs from healthy donors after LPS stimulation ranged from 0.93–8.67 ng/ml (IL-6), 1.17–4.12 ng/ml (TNF), 5.7–77.7 ng/ml (CXCL8/IL-8), 
0.054–0.334 ng/ml (IL-10), 0.010–0.058 ng/ml (IFN-), and 0.138–0.979 ng/ml (CCL5/RANTES; n = 3–4 independent experiments). Data were normalized 
to the average WT or healthy donor LPS result for each experiment. *, P ≤ 0.05; **, P < 0.01. (D) Schematic model of how mitochondrial ROS support  
LPS hyperresponsiveness in TRAPS.JEM VOL. 208, March 14, 2011 
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proteins BiP and CHOP appear normal in cells from TRAPS 
mice and patients (Simon et al., 2010), macrophages undergo-
ing ER stress can exhibit increased XBP-1 splicing without 
activation of many ER stress–induced genes (Martinon   
et al., 2010). In addition, TNFR1 has been shown to sense ER 
stress and mediate ER stress–induced JNK activation (Yang 
et al., 2006). Chronic ER stress or enhanced ER stress   
sensing in the setting of TNFR1 mutations could activate   
proinflammatory signaling pathways in a ROS-dependent 
fashion.  Future  research  should  more  specifically  address 
the mechanisms by which TNFR1 mutations enhance mito-
chondrial respiration.
Although the genetic mutations and defective trafficking of 
the mutant TNFR1 protein have been identified in TRAPS, 
current treatments, including TNF blockade, do not adequately 
control the symptoms of many TRAPS patients or prevent 
amyloidosis (Hull et al., 2002; Church et al., 2006). Our 
findings identify mitochondrial ROS as a driver of inflamma-
tion in TRAPS and potentially other autoinflammatory dis-
eases. In addition, the identification of mitochondria as a 
source of ROS contributing to LPS responsiveness in healthy 
cells has broad implications for future studies on the role of 
ROS in inflammatory responses by the normal immune sys-
tem. Although it has recently been shown that mitochondrial 
damage and inhibition of mitophagy can activate the NLRP3 
inflammasome and IL-1 cleavage in a ROS-dependent 
manner (Zhou et al., 2010b), our results suggest a more gen-
eral role for mitochondrial ROS in the induction of inflam-
matory cytokines upstream of inflammasome activation.   
In TRAPS, increased mitochondrial ROS results from en-
hanced  oxidative  phosphorylation.  Whether  the  increased 
ROS observed in cells from patients with autoinflammatory 
disease associated with NLRP3 mutations (Tassi et al., 2010) 
also originates from mitochondria is not yet known. Blockade   
of ROS production by mitochondria provides a new thera-
peutic strategy to decrease symptoms in TRAPS and other 
inflammatory states.
MATERIALS AND METHODS
Patient samples. Patients and controls were included in this study after   
informed consent under the approved clinical research protocol NIAMS   
94-AR-0105. TRAPS patients with structural mutations were heterozygous 
for structural TRAPS-associated mutations in Tnfrsf1A (H22Y, C33Y, T50M, 
C33G, C52G, C52F, C30Y, or del c.193-14). Patients with nonstructural 
TNFR1 mutations were heterozygous for Tnfrsf1A R92Q or P46L muta-
tions. PBMCs were collected by density centrifugation using Ficoll-Paque 
PLUS (GE Healthcare), with PBMCs collected at the interface.
Mice and MEFs. TNFR1 mutant mice have been previously described 
(Simon et al., 2010) and were used on the C57BL/6 background. gp91phox-
null mice on the C57BL/6 background (B6.129S-Cybbtm1Din/J; The Jackson 
Laboratory) were crossed to TRAPS C33Y mutant mice to generate mice 
containing both mutations. Presence of the heterozygous mutant TNFR1 
allele and absence of the gp91phox allele was confirmed by genotyping. 
NMF333 (p22phox mutant) mice (A.B6 Tyr+-Cybanmf333/J; The Jackson   
Laboratory) were compared with their isogenic control, AJ.Tyr mice (A.B6-
Tyr+/J; The Jackson Laboratory). MEFs were generated from embryonic day 
12–13 embryos of each genotype following established protocols. Nlrp3/ 
mice were provided by V. Dixit (Genentech, South San Francisco, CA), 
all cells; (c) rotenone, which suppresses mitochondrial electron 
transport but not ROS production, is not effective at blocking 
cytokine production; (d) cells harboring TNFR1 mutations 
associated with TRAPS have increased basal oxygen con-
sumption, respiratory capacity, and mitochondrial ROS, but 
respond normally in terms of the NOX-generated respiratory 
burst; (e) blockade of mitochondrial ROS production in 
TNFR1 mutant cells specifically reduces hyperresponsiveness to 
LPS. Mitochondrial ROS may provide an alternate source of 
ROS that allows normal or enhanced inflammatory responses 
in the setting of NOX deficiency (van de Loo et al., 2003; 
Hultqvist et al., 2004; George-Chandy et al., 2008; Meissner 
et al., 2010; van de Veerdonk et al., 2010) and may explain 
the associated inflammatory symptoms seen in CGD patients 
alongside their immunodeficiency (Rosenzweig, 2008).
These results identify mitochondria, which are a major 
source of physiological cellular ROS (Chance et al., 1979; 
Balaban et al., 2005), in the genesis of ROS that drive in-
flammation. Although the effectiveness of DPI is often at-
tributed to inhibition of NOXs, the ability of DPI to block 
cytokine production in cells devoid of the NOX subunit 
p22phox suggests that there are other sources of ROS impor-
tant in the inflammatory response. We show here that DPI is 
as potent an inhibitor of oxygen consumption as rotenone, 
which blocks complex I of the electron transport chain. DPI 
blocks oxygen consumption, mitochondrial ROS generation, 
and IL-6 production in a similar dose–response manner. Thus, 
DPI appears to exert its antiinflammatory effects through 
blockade of mitochondrial respiration. Moreover, many of 
the functions ascribed to NOXs in inflammation because of 
the use of flavin inhibitors such as DPI may actually be caused 
by mitochondria or other ROS-generating pathways. In sup-
port of this concept, Rho zero L929 cells that lack mitochon-
drial DNA and an intact mitochondrial respiratory chain have 
decreased production of IL-6 in response to TNF, although 
these results must be interpreted with caution given the dra-
matic metabolic changes in these cells (Schulze-Osthoff et al., 
1993). Our data showing that MitoQ blocks transcription of 
inflammatory  cytokines  implicates  mitochondrial  ROS  in 
this process. The increased MnSOD expression we find in 
TNFR1 mutant cells is an indicator of chronic oxidative 
stress (Miao and St Clair, 2009; Pani et al., 2009) that may 
feed back and cause even more dysregulated inflammation.
Several mechanisms may allow mutant TNFR1 to enhance 
oxygen consumption and ROS production. The endoplasmic 
reticulum, where mutant TNFR1 resides, can provide signals 
to activate mitochondrial respiration, including a calcium sig-
nal transduced by mitochondrial InsP3 receptors (Cárdenas   
et al., 2010). Mutant TNFR1 may increase activation of ribo-
flavin kinase, which can associate with TNFR1 (Yazdanpanah 
et al., 2009), leading to enhanced charging of FAD-dependent 
enzymes in the mitochondria. Another potential mechanism 
could involve low-level activation of ER stress signaling in-
volving XBP-1, which has been shown to induce hyperre-
sponsiveness to TLR stimulation reminiscent of what is seen 
in TRAPS. Although expression of the ER stress–induced 530 Mitochondrial ROS in autoinflammation | Bulua et al.
sodium vanadate, and protease inhibitor cocktail (Roche). 40 µg of total 
protein was applied to each lane and subjected to SDS-PAGE and Western 
blotting via enhanced chemiluminescence (GE Healthcare). The following 
primary antibodies were used: JNK1 (554286; BD), phospho-JNK (Thr183/
Tyr185, 9251), phospho-p38Thr180/Tyr182 (9215), phospho-ERK Thr202/
Tyr204 (9101), p38 (9212), ERK (9102) from Cell Signaling Technology. 
Multiple exposures were taken to select images with density within the dynamic 
range using Fuji Image Reader LAS-3000 software and band intensity was 
quantified using Multi Gauge software (Fujifilm Global). Bands of interest 
were normalized to the corresponding nonphosphorylated bands as indicated.
qRT-PCR. Total RNA was isolated from cells using RNeasy Mini kit 
(QIAGEN).  First-strand  cDNA  was  prepared  using  TaqMan  Reverse 
Transcription kit (Applied Biosystems). Equal amounts of cDNA were sub-
jected to PCR to quantitate IL-6 (Mm00446190_m1), SOD2 (mouse,   
Mm00449726_m1; human, Hs00167309_m1), and TXN (Hs00828652_m1) 
gene expression with the use of an ABI PRISM 7700 sequence-detection 
system.  Predesigned  primer/probe  sets  for  each  gene  were  purchased   
from Applied Biosystems. Probes specific for 2-microglobulin (mouse, 
Mm00437762_m1; human, Hs00187842) were used as internal controls. 
Each measurement in WT MEFs or healthy donors without treatment was 
normalized to expression of 2-microglobulin (Ct). For experiments   
incorporating treatments, measurements of untreated and treated cells were 
compared (Ct). The inverse log of the Ct was then calculated to give 
the relative fold change.
ATP level determination. ATP levels were determined using the Cell 
Titer-Glo luminol assay (Promega). Cells were plated in triplicate at 0.15 × 
106 cells/ml (MEFs) or 0.25 × 106 cells/ml (PBMCs) in sterile, white, 
opaque 96-well plates and incubated for 6 h. Assay was performed accord-
ing to the manufacturer’s instructions. ATP level was calculated in relation 
to cell number, as determined in parallel by the CyQuant Cell Prolifera-
tion Assay kit (Invitrogen).
Seahorse XF-24 metabolic flux analysis. Oxygen consumption rate and 
extracellular acidification rate were measured at 37°C using an XF24 extra-
cellular analyzer (Seahorse Bioscience). MEFs were seeded in 24-well plates 
for 24 h and human cells were treated with CELL-TAK (BD) for 30 min. 
Cells were changed to unbuffered DMEM (DMEM supplemented with   
25 mM glucose, 1 mM sodium pyruvate, 31 mM NaCl, 2 mM GlutaMax,   
pH 7.4) and incubated at 37°C in a non-CO2 incubator for 1 h All injection 
reagents were adjusted to pH 7.4 on the day of the assay. Four baseline mea-
surements were taken before sequential injection of mitochondrial inhibitors   
and antioxidants. Four readings were taken after each addition of dinitrophe-
nol (100 µM), DPI (5 µM or as indicated), rotenone (2 µM), MitoQ (1 µM),   
or dTPP (1 µM). Oxygen consumption rate and extracellular acidification 
rate were automatically calculated by the Seahorse XF-24 software. Every 
point represents an average of 3–6 different wells. After the assays, plates 
were saved and protein concentration in each well was determined using a 
BCA assay (Thermo Fisher Scientific).
Mitochondrial membrane potential. Mitochondrial membrane potential 
was measured by TMRM staining (Invitrogen). MEFs were incubated with 
200 nM TMRM for 15 min and then analyzed for fluorescence on a FACS-
Calibur flow cytometer (BD).
Mitochondrial DNA copy measurement. DNA was collected from WT 
and TNFR1 mutant MEFs using the Puregene core kit (QIAGEN). Real-time 
PCR was performed for cytochrome b (Cytb) and for nuclease-encoded 18S 
using SYBR green PCR Master Mix (Applied Biosystems) and the MJ research 
DNA Engine Opticon 2 fluorescence detection system (Bio-Rad Laboratories). 
Absolute Cytb DNA copies were normalized to the nuclear gene, 18S. Cytb, 
forward 5-CTTTGGGTCCCTTCTAGGAGTCTG-3, reverse 5- CGAA-
GAATCGGGTCAAGGTGGC-3; 18S, forward 5-CTTAGAGGGA-
CAAGTGGCGTTC-3, reverse 5-CGCTGAGCCAGTCAGTGTAG-3.
Casp1/ mice were provided by R. Flavell (Yale University, New Haven, 
CT), and Il1r/ mice were purchased from The Jackson Laboratory 
(B6.129S7-Il1r1tm1Imx/J). All animal procedures in mice were performed 
according to approved National Institute of Arthritis and Musculoskeletal 
and Skin Diseases animal protocols.
Cell stimulation and cytokine assays. PBMCs were incubated at 106 
cells/ml in a 96-well plate in RPMI medium plus 10% heat-inactivated FCS. 
MEFs were plated in a 96-well plate at 106 cells/ml in DMEM medium plus 
10% heat-inactivated FCS. Mouse peritoneal macrophages were collected by 
established methods from unmanipulated mice and plated at 106 cells/ml in 
a 96-well plate in RPMI medium plus 10% heat-inactivated FCS. Cells were 
allowed to adhere for 30 min in serum-free RPMI medium, followed by a 
wash. All cells were incubated with or without LPS (Ultrapure Salmonella 
minnesota R595; List Biological Laboratories Inc.) at 100 ng/ml (MEFs and 
peritoneal macrophages) or 10 ng/ml (PBMCs). After 6 h, supernatant was 
collected, centrifuged to remove cells and debris, and stored at 80°C for later 
analysis. In mouse peritoneal macrophages, 5 mM ATP (Sigma-Aldrich) was 
added for the last 15 min of incubation. IL-6 cytokine analysis was performed   
by ELISA using DuoSet ELISA kits (R&D Systems) for mouse and human 
IL-6. IFN- cytokine analysis was performed by ELISA using VeriKine kits 
for  mouse  and  human  IFN-  (PBL  Interferon  Source).  IL-1,  TNF, 
CXCL8/IL-8, IL-10, and CCL5/RANTES cytokine analysis was performed 
using a Bio-Plex Pro Bead Array (Bio-Rad Laboratories). Results were nor-
malized to cell number, as determined by the CyQuant cell proliferation as-
say (Invitrogen). The following inhibitors were obtained from Sigma-Aldrich 
and used at the following final concentrations: NAC 10 mM, rotenone 10 µM, 
DPI 5 µM, or as indicated. MitoQ and decylTPP were obtained from   
Antipodean Pharmaceuticals and used at 1 µM final concentration.
ROS detection. For DHR-based flow cytometric detection of intracellular 
ROS, whole blood was subjected to ACK lysis and washed. Cells were then 
incubated for five minutes with catalase (Sigma-Aldrich), DHR (Sigma- 
Aldrich), and HBSS buffer with Ca2+ and Mg2+ and without phenol red. 
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